Gluconate Calcium
Based on 1 publication(s) in Google Scholar
Gluconate (D-Gluconic acid) Calcium is an orally active glucose derivative. Gluconate Calcium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate Calcium inhibits ERK phosphorylation. Gluconate Calcium has antioxidant and antiplatelet activation activities. Gluconate Calcium has antitumor activity against colorectal cancer. Gluconate Calcium improves osteoarthritis, intestinal damage and acute lung injury.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 299-28-5
- Formula: C6H12O7.1/2Ca
- Molecular Weight:216.20
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Gluconate Calcium
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
Gluconate Calcium (0.5-3 mM; 5 min) inhibits thrombin-induced arachidonic acid peroxidation and superoxide anion production in platelets, reduces platelet protein oxidation/nitration, and decreases carbonyl group generation, thiol oxidation, and nitrotyrosine formation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Gluconate Calcium (50 mg/kg body weight; once a day for 5 weeks) regulates the changes in hematological parameters induced by Dimethylhydrazine (HY-W460407) in mice, reduces the levels of lipid peroxidation and nitric oxide (NO) in colon tissues, and improves the pathological changes of colon tissues[3].
Gluconate sodium (2500 ppm; in diet; p.o.; 15 days) increases the average daily gain of weaned piglets, reduces the feed-to-gain ratio, alleviates the intestinal injury induced by recombinant Escherichia coli, and improves the intestinal morphology[4].
Gluconate sodium (Calcium gluconate; 50 mg/kg; p.o.; 84 days) alleviates the symptoms of osteoarthritis induced by anterior cruciate ligament transection and partial medial meniscectomy in Sprague-Dawley rats, and inhibits joint stiffness and cartilage damage[5].
Gluconate sodium (Calcium gluconate; 12.5-50 mg/kg; i.p.; 30 min after modeling) alleviates lipopolysaccharide (LPS)-induced acute lung injury in mice, and inhibits the infiltration of inflammatory cells and the release of inflammatory cytokines[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 299-28-5
-
Appearance Solid
-
Molecular Weight 216.20
-
Formula C6H12O7.1/2Ca
-
Color White to off-white
-
SMILES
O[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)C(O)=O.[1/2Ca]
-
Synonyms
Calcium D-gluconate; Gluconic acid hemicalcium salt
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
H2O : 20 mg/mL (92.51 mM; Need ultrasonic)
DMSO : 1 mg/mL (4.63 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Saluk-Juszczak J. A comparative study of antioxidative activity of calcium-D-glucarate, sodium-D-gluconate and D-glucono-1,4-lactone in a human blood platelet model. Platelets. 2010;21(8):632-40. [Content Brief]
[2]. Kameue C, et al. Dietary sodium gluconate protects rats from large bowel cancer by stimulating butyrate production. J Nutr. 2004 Apr;134(4):940-4. [Content Brief]
[3]. Saleem TH, et al. Possible Protective Effects of Quercetin and Sodium Gluconate Against Colon Cancer Induction by Dimethylhydrazine in Mice. Asian Pac J Cancer Prev. 2015;16(14):5823-8. [Content Brief]
[4]. Zhang Y, et al. Dietary supplementation with sodium gluconate improves the growth performance and intestinal function in weaned pigs challenged with a recombinant Escherichia coli strain. BMC Vet Res. 2022 Aug 6;18(1):303. [Content Brief]
[5]. Kang SJ, et al. Protective effects of calcium gluconate on osteoarthritis induced by anterior cruciate ligament transection and partial medial meniscectomy in Sprague-Dawley rats. J Orthop Surg Res. 2014 Mar 7;9(1):14. [Content Brief]
[6]. Liu L, et al. Effects of calcium gluconate on lipopolysaccharide-induced acute lung injury in mice. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2931-2935. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 4.6253 mL | 23.1267 mL | 46.2535 mL | 115.6337 mL |
| H2O | 5 mM | 0.9251 mL | 4.6253 mL | 9.2507 mL | 23.1267 mL |
| 10 mM | 0.4625 mL | 2.3127 mL | 4.6253 mL | 11.5634 mL | |
| 15 mM | 0.3084 mL | 1.5418 mL | 3.0836 mL | 7.7089 mL | |
| 20 mM | 0.2313 mL | 1.1563 mL | 2.3127 mL | 5.7817 mL | |
| 25 mM | 0.1850 mL | 0.9251 mL | 1.8501 mL | 4.6253 mL | |
| 30 mM | 0.1542 mL | 0.7709 mL | 1.5418 mL | 3.8545 mL | |
| 40 mM | 0.1156 mL | 0.5782 mL | 1.1563 mL | 2.8908 mL | |
| 50 mM | 0.0925 mL | 0.4625 mL | 0.9251 mL | 2.3127 mL | |
| 60 mM | 0.0771 mL | 0.3854 mL | 0.7709 mL | 1.9272 mL | |
| 80 mM | 0.0578 mL | 0.2891 mL | 0.5782 mL | 1.4454 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.